HOME >> BIOLOGY >> NEWS
Tailored treatments: Promising designer drug provides new insight into cancer biology

Scientists are making progress toward unraveling the molecular mysteries that underlie cancer progression and treatment resistance. Two studies in the November 2006 issue of the journal Cancer Cell, published by Cell Press, provide mechanistic details that may explain why the small-molecule chemical ABT-737 is emerging as a unique and effective anticancer agent. The studies also demonstrate that pharmacological manipulation of specific signaling molecules can make resistant cancer cells sensitive to treatment with ABT-737. These studies provide support for the idea that examination of the molecular profile of individual tumors can provide useful information for guiding treatment decisions.

Cell survival molecules like BCL-2 are abnormally regulated and overactive in many tumors and are thought to promote cancer progression and protect cancer cells from cancer therapies. In normal cells, BH3 proteins bind to and inhibit BCL-2. Therefore, researchers have attempted to design compounds that are similar to these natural antagonists to use as weapons against cancer cells. The synthetic BH3 mimetic ABT-737 has been shown to interact strongly with BCL-2 but weakly with other BCL-2 family members, such as MCL-1, and has been described as an excellent candidate for further research.

Dr. Michael Andreeff from The University of Texas M.D. Anderson Cancer Center and colleagues found that ABT-737 effectively kills acute myeloid leukemia (AML) cells without affecting normal blood cells. However, the researchers observed that cancer cells with high levels of the cell survival molecule MCL-1 were much less sensitive to ABT-737 treatment. Further experiments demonstrated that pharmacologic inhibition of MCL-1 or inhibition of MCL-1 through RNA interference restored sensitivity of leukemic cells and definitively identified MCL-1 as an ABT-737 resistance factor. The researchers suggest that specific BCL-2 family proteins may define resistance to this BH3 mimetic.<
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
13-Nov-2006


Page: 1 2

Related biology news :

1. Revolutionary new medical treatments: International effort to steer around obstacles
2. Promising protein may prevent eye damage in premature babies
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising preclinical results with live attenuated H5N1 vaccines
5. Promising new research on hereditary diseases
6. Promising cell protein may play role in infection and dry eye
7. Promising anti-TB compound finally can be synthesized with ease
8. Promising results in the battle against incurable ALS muscle disease
9. Promising new preventative treatment option for population of men at high risk of prostate cancer
10. New designer lipid-like peptide with lipid nanostructures for drug delivery systems
11. Two designer drugs hit same lung cancer target, but only one is effective

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2020)... ... February 13, 2020 , ... ... Global Assessment Report: The Laboratory Analytical & Life Science Instrumentation Industry. The report ... the gold standard of market intelligence for the $70 billion laboratory market for ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... LaunchPort™ medical device accelerator in Port Covington, Baltimore. The newly formed company is ... be addressed to manage increased demand for home dialysis treatments. The start-up company ...
(Date:2/5/2020)... ... 2020 , ... Crystal Diagnostics (CDx) announced today that the ... to proprietary liquid crystal technology for rapid and accurate detection of foodborne pathogens. ... December 3, 2019. Together, these patents protect the company’s liquid crystal technology currently ...
Breaking Biology News(10 mins):
(Date:2/19/2020)... ... 18, 2020 , ... Intech , the leader in ... and unified global brand identity, as it celebrates its 20th anniversary. , Fueled ... as an enthusiasm for designing and manufacturing state-of-the-art medical devices, Intech has grown ...
(Date:2/13/2020)... ... February 12, 2020 , ... ... (PV) solutions and services, is adopting Veeva Vault Safety™ as part ... requirement for fast assessment of data, processing of safety information such as SUSARs ...
(Date:2/11/2020)... BALTIMORE (PRWEB) , ... February 11, 2020 , ... ... biosolids and residuals solutions services in North America, today announced that the City ... long-term solution to its biosolids management needs. Commencing in April of 2020, Synagro ...
(Date:2/5/2020)... (PRWEB) , ... February 04, 2020 , ... ... tools for characterizing microbiome populations down to the strain level, has announced a ... sell Shoreline Biome’s microbiome kits and other products to companies and research organizations ...
Breaking Biology Technology:
Cached News: